Applegate Robert J, Sacrinty Matthew, Kutcher Michael, Santos Renato, Gandhi Sanjay, Little William
Wake Forest University School of Medicine, Section of Cardiology, Winston-Salem, North Carolina 27157-1045, USA.
Catheter Cardiovasc Interv. 2008 Jul 1;72(1):7-12. doi: 10.1002/ccd.21566.
To compare late outcomes with the routine use of drug-eluting stents (DES) compared with bare-metal stents (BMS) during percutaneous intervention (PCI) of saphenous vein grafts (SVGs).
Safety concerns >1 year from stent implantation have been raised about DES used for PCI of SVGs in a small randomized clinical trial. However, there are few studies comparing late outcomes of DES and BMS in routine clinical practice.
Clinical outcomes (nonfatal MI, cardiac mortality) were assessed in 74 consecutive patients who received BMS and 74 consecutive propensity score matched patients that received DES for PCI of SVGs. Clinical follow-up was censored at 2 years +/- 30 days for both stent groups.
At 2 years, the hazard ratio for DES compared with BMS for PCI of SVGs for target vessel revascularization was 0.54 (0.21-1.36), nonfatal MI or cardiac death was 0.68 (0.27-1.68), cardiac mortality 1.19 (0.32-4.45), and stent thrombosis 0.49 (0.09-2.66). Similar outcomes were observed stratified by propensity score quintile.
The routine clinical use of DES for PCI of SVGs was associated with a safety profile that was similar to that of bare metal stents with a clear trend toward a less frequent need for reinterventions.
比较在隐静脉搭桥血管(SVG)经皮介入治疗(PCI)中常规使用药物洗脱支架(DES)与裸金属支架(BMS)的远期疗效。
在一项小型随机临床试验中,有人对用于SVG的PCI的DES植入后超过1年的安全性提出了担忧。然而,在常规临床实践中,比较DES和BMS远期疗效的研究很少。
对74例接受BMS的连续患者和74例接受DES进行SVG的PCI且倾向评分匹配的连续患者的临床结局(非致命性心肌梗死、心源性死亡)进行评估。两个支架组的临床随访均在2年±30天进行截尾。
2年时,DES与BMS用于SVG的PCI的靶血管血运重建的风险比为0.54(0.21 - 1.36),非致命性心肌梗死或心源性死亡为0.68(0.27 - 1.68),心源性死亡为1.19(0.32 - 4.45),支架血栓形成率为0.49(0.09 - 2.66)。按倾向评分五分位数分层观察到相似的结果。
DES在SVG的PCI中的常规临床应用与裸金属支架具有相似的安全性,且再次干预的需求明显减少。